OMEICOS Therapeutics
Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered a broad range of technological and disease areas. In his most recent position, Dr. Kirschbaum served as head of Global Research and Early Development at Merck Serono where he was a member of the board.
This person is not in the org chart
This person is not in any offices
OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.